- AbbVie reports Phase 3 EPCORE DLBCL-4: epcoritamab+lenalidomide cut PFS vs R‑GemOx (HR 0.40 US, 0.44 ex‑US). Company to engage regulators and prepare data presentation.
- AbbVie: EMA CHMP gave positive opinions for upadacitinib (RINVOQ) — alopecia areata (15/30 mg) and non‑segmental vitiligo (15 mg) after Phase 3 trials; EU decisions expected soon.
TradingView
Key facts: AbbVie: Epcoritamab combo cuts DLBCL PFS; CHMP backs RINVOQ
AbbVie reports Phase 3 EPCORE DLBCL-4: epcoritamab+lenalidomide cut PFS vs R‑GemOx (HR 0.40 US, 0.44 ex‑US). Company to engage regulators and prepare data presentation.AbbVie: EMA